Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) CEO Sells $486,060.00 in Stock

Posted by Brenda Bartman on Sep 13th, 2026

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) CEO Renee Gala sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $243.03, for a total transaction of $486,060.00. Following the completion of the sale, the chief executive officer owned 143,394 shares of the company’s stock, valued at approximately $34,849,043.82. This trade represents a 1.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Trading Up 2.2%

NASDAQ JAZZ opened at $245.80 on Friday. Jazz Pharmaceuticals PLC has a twelve month low of $123.88 and a twelve month high of $266.38. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.58 and a current ratio of 1.78. The stock has a market cap of $15.96 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 0.22 and a beta of 0.36. The firm’s 50 day moving average price is $249.37 and its two-hundred day moving average price is $223.73.

Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 EPS for the quarter, missing the consensus estimate of $6.18 by ($0.47). Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.11 billion. During the same period last year, the business earned ($8.25) EPS. The business’s quarterly revenue was up 15.5% on a year-over-year basis. Equities analysts anticipate that Jazz Pharmaceuticals PLC will post 21.5 EPS for the current year.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. California State Teachers Retirement System raised its holdings in Jazz Pharmaceuticals by 24,585.6% during the second quarter. California State Teachers Retirement System now owns 15,714,136 shares of the specialty pharmaceutical company’s stock valued at $3,786,635,000 after buying an additional 15,650,479 shares in the last quarter. Vestal Point Capital LP bought a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $127,344,000. Franklin Resources Inc. increased its holdings in shares of Jazz Pharmaceuticals by 164.0% during the 4th quarter. Franklin Resources Inc. now owns 1,818,911 shares of the specialty pharmaceutical company’s stock valued at $309,215,000 after acquiring an additional 1,129,995 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Jazz Pharmaceuticals by 160.2% in the 4th quarter. Bank of New York Mellon Corp now owns 1,161,857 shares of the specialty pharmaceutical company’s stock valued at $197,516,000 after acquiring an additional 715,361 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Jazz Pharmaceuticals by 258.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 548,000 shares of the specialty pharmaceutical company’s stock valued at $93,160,000 after acquiring an additional 395,000 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on JAZZ. Needham & Company LLC increased their price target on shares of Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Bank of America upped their price objective on shares of Jazz Pharmaceuticals from $281.00 to $307.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft increased their target price on shares of Jazz Pharmaceuticals from $287.00 to $300.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. Robert W. Baird lifted their target price on shares of Jazz Pharmaceuticals from $252.00 to $280.00 and gave the company an “outperform” rating in a research note on Tuesday, August 4th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Jazz Pharmaceuticals from $265.00 to $276.00 and gave the company an “overweight” rating in a report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $286.72.

Check Out Our Latest Research Report on Jazz Pharmaceuticals

About Jazz Pharmaceuticals

(Get Free Report)

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a global biopharmaceutical company focused on developing and commercializing medicines for disorders in neuroscience and oncology. The company concentrates on conditions with significant unmet medical needs, including sleep disorders, epilepsy, rare diseases and certain cancers.

Its neuroscience portfolio includes Xywav and Xyrem, oxybate-based treatments for narcolepsy, with Xywav also indicated for idiopathic hypersomnia in adults. Jazz also markets Epidiolex in the United States, known as Epidyolex in some international markets, a cannabidiol-based medicine for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

In oncology, Jazz’s products include Rylaze, an asparaginase therapy used as part of treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca, used for certain patients with metastatic small cell lung cancer; and Vyxeos, a chemotherapy formulation for certain cases of newly diagnosed therapy-related acute myeloid leukemia or AML with myelodysplasia-related changes.